چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | امیررضا ناصری |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | کمیته تحقیقات دانشجویی |
| کد مقاله | 83471 |
| عنوان فارسی مقاله | The effects of melatonin supplementation on cognitive outcomes in multiple sclerosis; a systematic review |
| عنوان لاتین مقاله | The effects of melatonin supplementation on cognitive outcomes in multiple sclerosis; a systematic review |
| نوع ارائه | پوستر |
| عنوان کنگره / همایش | Eighth MENACTRIMS Congress |
| نوع کنگره / همایش | بین المللی |
| کشور محل برگزاری کنگره/ همایش | United Arab Emirates |
| شهر محل برگزاری کنگره/ همایش | Abu Dhabi |
| سال انتشار/ ارائه شمسی | 1402 |
| سال انتشار/ارائه میلادی | 2023 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1402/09/17 الی 1402/09/18 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | https://doi.org/10.1016/j.msard.2023.105167 |
| آدرس علمی (Affiliation) نویسنده متقاضی | Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. |
| نویسنده | نفر چندم مقاله |
|---|---|
| امیررضا ناصری | اول |
| سروش مرسلی | دوم |
| زهرا صباحی | سوم |
| زهرا حکیم زاده | پنجم |
| ثنا حمیدی | ششم |
| الناز قلی پور خلیلی | هفتم |
| سروین سنایی اسکویی | هشتم |
| مهناز طالبی | نهم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Background: Melatonin is a neurohormone secreted predominantly by the pineal gland that is found to be associated with improving cognitive outcomes in Alzheimer’s Diseases (1). This research desires to evaluate the cognitive effects of exogenous melatonin supplementations in patients with multiple sclerosis (MS). Methods: This study was executed following the PRISMA 2020 statement. Ovid, PubMed, Scopus, Embase, and Web of Science databases were searched for a comprehensive coverage of the published studies on this topic and there was not time and study design restriction. Results: Out of 1304 results of database searches, finally, 3 RCTs, were included. Jalluoli and colleagues, in an RCT in 2022, studied the cognitive effects of nocturnal ingestion of 6 mg melatonin for 6 months in 14 RRMS patients, based on Montreal cognitive assessment (MoCA) and simple Reaction time (SRT), the results showed that melatonin could safely improve cognitive function in MS patients (2). Roostaei and colleagues established an RCT to observe the effects of 3mg melatonin for 12 months on motor, cognitive, and neuroimaging indices in 25 RRMS patients and the findings showed beneficial Cognitive outcomes in Modified Fatigue Impact Scale (MFIS) (3). Finally, self-reported cognitive function, in a cross-over RCT, Drake et al. in 31 patients with various subtypes (RRMS, SPMS, and PPMS) did not differed significantly between melatonin and placebo groups (4). Discussion: This study found scattered, inconsistent and limited evidence regarding the cognitive efficacy of melatonin supplementation in MS, which suggested future well-designed clinical studies on this topic. Funding: The research protocol was approved and supported by the Student Research Committee, Tabriz University of Medical Sciences (grant number: 70831). |
| کلمات کلیدی | multiple sclerosis; melatonin; systematic review |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Melatonin.pdf | 1402/11/09 | 1477793 | دانلود |
| MENACTRIMS 2023 - 1.pdf | 1402/09/22 | 3600749 | دانلود |
